Summary
The tissue distribution of anti-tumour vascular endothelium monoclonal antibody (TES-23) produced by immunizing with plasma membrane vesicles from isolated rat tumour-derived endothelial cells (TECs) was assessed in various tumour-bearing animals. Radiolabelled TES-23 dramatically accumulated in KMT-17 fibrosarcoma, the source of isolated TECs after intravenous injection. In Meth-A fibrosarcoma, Colon-26 adenocarcinoma in BALB/c mice and HT-1080 human tumour tissue in nude mice, radioactivities of 125I-labelled TES-23 were also up to 50 times higher than those of control antibody with little distribution to normal tissues. The selective recognition of TES-23 to TECs was competitively blocked by preadministration of unlabelled TES-23 in vivo. Furthermore, immunostaining of human tissue sections showed specific binding of TES-23 on endothelium in oesophagus cancers. These results indicate that tumour vascular endothelial cells express common antigen in different tumour types of various animal species. In order to clarify the efficacy of TES-23 as a drug carrier, an immunoconjugate, composed of TES-23 and neocarzinostatin, was tested for its anti-tumour effect in rats bearing KMT-17 fibrosarcomas. The immunoconjugate (TES-23-NCS) caused marked regression of the tumour, accompanied by haemorrhagic necrosis. Thus, from a clinical view, TES-23 would be a novel drug carrier because of its high specificity to tumour vascular endothelium and its application to many types of cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Brooks, PC, Clark, RA & Cheresh, DA (1994). Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 264: 569–571.
Brown, JP, Woodbury, RG, Hart, CE, Hellstrom, I & Hellstrom, KE (1981). Quantitative analysis of melanoma associated antigen p97 in normal neoplastic tissues. Proc Natl Acad Sci USA 78: 539–543.
Burrows, FJ & Thorpe, PE (1993). Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature. Proc Natl Acad Sci USA 90: 8996–9000.
Camera, L, Kinuya, S, Pai, LH, Garmestani, K, Brechbiel, MW, Gansow, OA, Paik, CH, Pastan, I & Carrasquillo, JA (1993). Preclinical evaluation of 111In-labeled B3 monoclonal antibody: biodistribution and imaging studies in nude mice bearing human epidermoid carcinoma xenografts. Cancer Res 53: 2834–2839.
Denekamp, J (1984). Vasculature as a target for tumor therapy. Prog Appl Microcirc 4: 28–38.
Dvorak, HF, Nagy, JA, Dvorak, JT & Dvorak, AM (1988). Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am J Pathol 133: 95–109.
Dvorak, HF, Nagy, JA & Dvorak, AM (1991). Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 3: 77–85.
Epenetos, AA, Snook, D, Durbin, H, Johnson, PM & Taylor-Papadimitriou, J (1986). Limitations of radiolabeled monoclonal antibodies for localization of human neoplasms. Cancer Res 46: 3183–3191.
Friden, PM, Walus, LR, Watson, P, Doctrow, SR, Kozarich, JW, Backman, C, Bergman, H, Hoffer, B, Bloom, F & Granholm, AC (1993). Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259: 373–378.
Griffioen, AW, Damen, CA, Blijham, GH & Groenewegen, G (1996a). Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium. Blood 88: 667–673.
Griffioen, AW, Damen, CA, Martinotti, S, Blijham, GH & Groenewegen, G (1996b). Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Cancer Res 56: 1111–1117.
Haranaka, K, Satomi, N & Sakurai, A (1984). Antitumor activity of murine tumor necrosis factor (TNF) against transplanted murine tumors and heterotransplanted human tumors in nude mice. Int J Cancer 34: 263–267.
Hellstrom, KE & Hellstrom, I (1985). Monoclonal anti-melanoma antibodies and their possible clinical use. In: Monoclonal Antibodies for Cancer Detection and Therapy, Baldwin RW Byerrs VS Academic Press: London 17–51.
Heuser, LS & Miller, FN (1986). Differential macromolecular leakage from the vasculature of tumors. Cancer 57: 461–464.
Juweid, M, Neumann, R, Paik, C, Perez-Bacete, MJ, Sato, J, vanOsdol, W & Weinstein, JN (1992). Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 52: 5144–5153.
Kennel, SJ, Falcioni, R & Wesley, JW (1991). Microdistribution of specific rat monoclonal antibodies to mouse tissues and human xenografts. Cancer Res 51: 1529–1536.
Kitamura, K, Takahashi, T, Kotani, T, Miyagaki, T, Yamaoka, N, Tsurumi, H, Noguchi, A & Yamaguchi, T (1992). Local administration of monoclonal antibody–drug conjugate: a new strategy to reduce the local recurrence of colorectal cancer. Cancer Res 52: 6323–6328.
Laborda, J, Douillard, JY, Burg, C, Lizzio, EF, Ridge, J, Levenbook, I & Hoffman, T (1990). Pharmacokinetic studies of mouse monoclonal antibodies to a rat colon carcinoma: I. Comparison of biodistribution in normal rats, syngeneic tumor-bearing rats, or tumor-bearing nude mice. J Nucl Med 31: 1028–1034.
Madri, JA & Williams, SK (1983). Capillary endothelial cell cultures: phenotypic modulation by matrix components. J Cell Biol 97: 153–165.
Manda, T, Shimomura, K, Mukumoto, S, Kobayashi, K, Mizota, T, Hirai, O, Matsumoto, S, Oku, T, Nishigaki, F & Mori, J (1987). Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity. Cancer Res 47: 3707–3711.
Melder, RJ, Koenig, GC, Witwer, BP, Safabakhsh, N, Munn, LL & Jain, RK (1996). During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 2: 992–997.
Modzelewski, RA, Davies, P, Watkins, SC, Auerbach, R, Chang, MJ & Johnson, CS (1994). Isolation and identification of fresh tumor derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 54: 336–339.
Nose, K, Saito, H & Kuroki, T (1990). Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell Growth Differ 1: 511–518.
Ohizumi, I, Tsunoda, S, Taniguchi, K, Saito, H, Esaki, K, Makimoto, H, Wakai, Y, Tsutsumi, Y, Nakagawa, S, Utoguchi, N, Kaiho, S, Ohsugi, Y & Mayumi, T (1997). Antibody-based therapy targeting tumor vascular endothelial cells suppresses solid tumor growth in rats. Biochem Biophys Res Commun 236: 493–496.
Ohizumi, I, Tsunoda, S, Taniguchi, K, Saito, H, Esaki, K, Koizumi, K, Makimoto, H, Wakai, Y, Matsui, J, Tsutsumi, Y, Nakagawa, S, Utoguchi, N, Ohsugi, Y & Mayumi, T (1998). Monoclonal antibodies recognize antigens expressed on rat tumor vasculature. Int J Cancer 77: 561–566.
Pai, LH, Wittes, R, Setser, A, Willingham, MC & Pastan, I (1996). Treatment of advanced solid tumors with immunotoxin LMB-1: An antibody linked to Pseudomonas exotoxin. Nat Med 3: 350–353.
Reiter, Y, Pai, LH, Brinkmann, U, Wang, Q & Pastan, I (1994). Antitumor activity and pharmacokinetics in mice of recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Cancer Res 54: 2714–2718.
Rettig, WJ, Garin-Chesa, P, Healey, JH, Su, SL, Jaffe, EA & Old, LJ (1992). Identification of endosialin, a cell surface glycoprotein of vascular endothelial cells in human cancer. Proc Natl Acad Sci USA 89: 10832–10836.
Rowland, GF (1987). Monoclonal antibodies as carriers for drug delivery systems. In: Drug Delivery Systems: Fundamentals and Techniques, Johnson P Lloyd-Jones JG VCH Publishers: Chichester 81–94.
Scott, RE (1976). Plasma-membrane vesiculation: a new technique for isolation of plasma membranes. Science 194: 743–745.
Takahashi, T, Yamaguchi, T, Kitamura, K, Noguchi, A, Honda, M & Otsuji, E (1990). Missile therapy for colorectal and pancreatic cancers: clinical trial of monoclonal antibody, A7-NCS, for 73 patients with colorectal and pancreatic cancers. Jpn J Cancer Chemother 17: 1111–1119.
Thorpe, PE & Burrows, FJ (1995). Antibody-directed targeting of the vasculature of solid tumors. Breast Cancer Res Treat 36: 237–251.
Utoguchi, N, Dantakean, A, Makimoto, H, Wakai, Y, Tsutsumi, Y, Nakagawa, S & Mayumi, T (1995a). Isolation and properties of tumor-derived endothelial cells from rat KMT-17 fibrosarcoma. Jpn J Cancer Res 86: 193–201.
Utoguchi, N, Mizuguchi, H, Saeki, K, Ikeda, K, Tsutsumi, Y, Nakagawa, S & Mayumi, T (1995b). Tumor-conditioned medium increases macromolecular permeability of endothelial cell monolayer. Cancer Lett 89: 7–14.
Utoguchi, N, Mizuguchi, H, Dantakean, A, Makimoto, H, Wakai, Y, Tsutsumi, Y, Nakagawa, S & Mayumi, T (1996). Effect of tumour cell-conditioned medium on endothelial macromolecular permeability and its correlation with collagen. Br J Cancer 73: 24–28.
Watanabe, N, Niitsu, Y, Umeno, H, Sone, H, Neda, H, Yamauchi, N, Maeda, M & Urushizaki, I (1988). Synergistic cytotoxic and antitumor effects of recombinant human tumor necrosis factor and hyperthermia. Cancer Res 48: 650–653.
Wu, NZ, Klitzman, B, Dodge, R & Dewhirst, MW (1992). Diminished leukocyte-endothelium interaction in tumor microvessels. Cancer Res 52: 4265–4268.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Tsunoda, S., Ohizumi, I., Matsui, J. et al. Specific binding of TES-23 antibody to tumour vascular endothelium in mice, rats and human cancer tissue: A novel drug carrier for cancer targeting therapy. Br J Cancer 81, 1155–1161 (1999). https://doi.org/10.1038/sj.bjc.6690823
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690823